TNSN92070A1 - Les analogues du necleoside de 13-oxathiolane - Google Patents

Les analogues du necleoside de 13-oxathiolane

Info

Publication number
TNSN92070A1
TNSN92070A1 TNTNSN92070A TNSN92070A TNSN92070A1 TN SN92070 A1 TNSN92070 A1 TN SN92070A1 TN TNSN92070 A TNTNSN92070 A TN TNSN92070A TN SN92070 A TNSN92070 A TN SN92070A TN SN92070 A1 TNSN92070 A1 TN SN92070A1
Authority
TN
Tunisia
Prior art keywords
oxathiolane
analogs
necleoside
relates
oxathiolan
Prior art date
Application number
TNTNSN92070A
Other languages
English (en)
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10699340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN92070(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of TNSN92070A1 publication Critical patent/TNSN92070A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/38—Nucleosides
    • C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'INVENTION SE RAPPORTE AUX ANALOGUES DU NUCLEOSIDE 1,3- OXATHIOLANE ET LEUR EMPLOI DANS LE TRAITEMENT ES INFECTIONS VIRALES. CETTE INVENTION SE RAPPORTE PLUS PRECISEMENT A (-)-4-AMINO-5-FLUORO-1-(2- HYDROXYMETHYL-1,3-OXATHIOLAN-5-YL)-(1H)-PYRIMIDIN-2- ONE, A SES DERIVES ACCEPTABLES EN PHARMACIE AINSI QU'A SES FORMULATIONS PHARMACEUTIQUES
TNTNSN92070A 1991-08-01 1992-07-31 Les analogues du necleoside de 13-oxathiolane TNSN92070A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919116601A GB9116601D0 (en) 1991-08-01 1991-08-01 1,3-oxathiolane nucleoside analogues

Publications (1)

Publication Number Publication Date
TNSN92070A1 true TNSN92070A1 (fr) 1993-06-08

Family

ID=10699340

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN92070A TNSN92070A1 (fr) 1991-08-01 1992-07-31 Les analogues du necleoside de 13-oxathiolane

Country Status (41)

Country Link
US (2) US5538975A (fr)
EP (2) EP1155695B1 (fr)
JP (1) JP2960778B2 (fr)
KR (1) KR100242454B1 (fr)
CN (5) CN101074228A (fr)
AP (1) AP321A (fr)
AT (2) ATE448787T1 (fr)
AU (1) AU659668B2 (fr)
BG (1) BG61693B1 (fr)
CA (2) CA2682254C (fr)
CZ (1) CZ283765B6 (fr)
DE (2) DE69232845T2 (fr)
DK (2) DK0526253T3 (fr)
EE (1) EE03002B1 (fr)
EG (1) EG20193A (fr)
ES (2) ES2335968T3 (fr)
FI (1) FI940435A (fr)
GB (1) GB9116601D0 (fr)
GE (1) GEP20002094B (fr)
HK (2) HK1008672A1 (fr)
HN (1) HN1997000118A (fr)
HU (2) HUT70030A (fr)
IL (1) IL102616A (fr)
MA (1) MA22919A1 (fr)
MD (1) MD1434C2 (fr)
MX (1) MX9204474A (fr)
NO (3) NO300842B1 (fr)
NZ (1) NZ243637A (fr)
OA (1) OA09883A (fr)
PH (1) PH30983A (fr)
PT (2) PT1155695E (fr)
RS (1) RS49993B (fr)
RU (1) RU2126405C1 (fr)
SG (1) SG68541A1 (fr)
SK (1) SK280131B6 (fr)
TJ (1) TJ244R3 (fr)
TN (1) TNSN92070A1 (fr)
TW (2) TW366347B (fr)
WO (1) WO1993003027A1 (fr)
YU (1) YU49259B (fr)
ZA (1) ZA925668B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
CA2171550C (fr) * 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides avec activite virale anti-hepatite b
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
ATE346651T1 (de) 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
CN1196701C (zh) * 1997-03-19 2005-04-13 埃莫里大学 1,3－氧硒戊环核苷的合成及抗人类免疫缺陷病毒和抗乙肝病毒活性
CA2285577A1 (fr) 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Utilisation de mkc-442 en combinaison avec d'autres agents antiviraux
CN1141305C (zh) 1998-08-12 2004-03-10 三角药物公司 生产1,3-氧硫戊环核苷的方法
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
EP1380303B1 (fr) 1998-11-02 2008-09-17 Gilead Sciences, Inc. Thérapie combinée pour le traitement du virus de l'Hepatite B
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
JP2003528138A (ja) * 2000-03-29 2003-09-24 ジョージタウン・ユニバーシティ デルタ肝炎ウイルス感染症の治療法
CA2308559C (fr) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones utiles pour la preparation d'analogues de nucleosides antiviraux
ATE383355T1 (de) * 2001-03-01 2008-01-15 Abbott Lab Polymorph und andere kristallinische formen von zusammen-ftc
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
AU2002364160A1 (en) * 2001-12-14 2003-06-30 Pharmasset Ltd. Preparation of intermediates useful in the synthesis of antiviral nucleosides
EP3025718A1 (fr) 2003-01-14 2016-06-01 Gilead Sciences, Inc. Compositions et procédés pour une thérapie antivirale combinée
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN100360528C (zh) * 2005-08-31 2008-01-09 四川大学 4-氨基-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基)-2(1h)-嘧啶酮的制备方法
WO2007077505A2 (fr) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited L-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1,3]oxathiolan-2-carboxylate crystallin et procede d'elaboration correspondant
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
BRPI0922508A8 (pt) * 2008-12-23 2016-01-19 Pharmasset Inc Análogos de nucleosídeo
CA2748057C (fr) 2008-12-23 2018-07-03 Pharmasset, Inc. Phosphoramidates de nucleosides
JP5793084B2 (ja) 2008-12-23 2015-10-14 ギリアド ファーマセット エルエルシー プリンヌクレオシドの合成
WO2010113039A1 (fr) * 2009-04-03 2010-10-07 Medical Research Council Mutants de cytidine désaminase induite par activation (aid) et procédés d'utilisation
EP2377862A1 (fr) 2010-03-29 2011-10-19 Esteve Química, S.A. Procédé pour l'obtention d'emtricitabine
CN102858790A (zh) 2010-03-31 2013-01-02 吉利德制药有限责任公司 核苷氨基磷酸酯
EP2802396B1 (fr) 2012-01-10 2018-11-14 C.C. Jensen A/S Méthode de nettoyage de l'huile dégradée
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DE2950317A1 (de) * 1979-12-14 1981-06-19 Agfa-Gevaert Ag, 5090 Leverkusen Elektrothermographische vorrichtung
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
DK0674634T3 (da) * 1989-02-08 2003-08-04 Iaf Biochem Int Fremgangsmåde til fremstilling af substituerede 1,3-oxathiolaner med antivirale egenskaber
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
RU2116789C1 (ru) * 1991-03-06 1998-08-10 Дзе Велкам Фаундейшн Лимитед Способ ингибирования вирусных инфекций гепатита в
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (fr) * 1991-04-17 1992-10-29 Yale University Procede de traitement ou de prevention du virus de l'hepatite b
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues

Also Published As

Publication number Publication date
DE69232845D1 (de) 2002-12-19
EP0526253A1 (fr) 1993-02-03
NZ243637A (en) 1995-03-28
TW366347B (en) 1999-08-11
IL102616A0 (en) 1993-01-14
CZ283765B6 (cs) 1998-06-17
SK280131B6 (sk) 1999-08-06
HK1008672A1 (en) 1999-05-14
US5538975A (en) 1996-07-23
SK10494A3 (en) 1994-12-07
MD1434C2 (ro) 2000-12-31
ATE227720T1 (de) 2002-11-15
MA22919A1 (fr) 1993-04-01
ATE448787T1 (de) 2009-12-15
SG68541A1 (en) 1999-11-16
YU72303A (sh) 2006-05-25
DK0526253T3 (da) 2003-03-17
ES2335968T3 (es) 2010-04-07
NO2008009I1 (no) 2008-06-30
KR100242454B1 (ko) 2000-03-02
AP321A (en) 1994-02-28
CN101066970A (zh) 2007-11-07
EP1155695A1 (fr) 2001-11-21
EP0526253B1 (fr) 2002-11-13
YU74992A (sh) 1995-12-04
DK1155695T3 (da) 2010-04-06
DE69232845T2 (de) 2003-04-24
HU9400285D0 (en) 1994-05-30
JPH07500317A (ja) 1995-01-12
NO940322D0 (no) 1994-01-31
HN1997000118A (es) 1999-11-12
OA09883A (en) 1994-09-15
RS49993B (sr) 2008-09-29
BG98616A (bg) 1995-03-31
CA2114221A1 (fr) 1993-02-18
NO2005017I1 (no) 2005-09-05
EE03002B1 (et) 1997-06-16
MX9204474A (es) 1993-12-01
CN1070191A (zh) 1993-03-24
CN1034810C (zh) 1997-05-07
FI940435A0 (fi) 1994-01-28
CN1132073A (zh) 1996-10-02
ES2186667T3 (es) 2003-05-16
AP9200414A0 (en) 1992-07-31
AU2340892A (en) 1993-03-02
CA2682254A1 (fr) 1993-02-18
CN101074228A (zh) 2007-11-21
CN100542535C (zh) 2009-09-23
ZA925668B (en) 1993-04-28
EP1155695B1 (fr) 2009-11-18
CA2682254C (fr) 2012-02-21
NO2005017I2 (no) 2007-10-01
PT1155695E (pt) 2010-02-02
GB9116601D0 (en) 1991-09-18
NO940322L (no) 1994-03-21
WO1993003027A1 (fr) 1993-02-18
RU2126405C1 (ru) 1999-02-20
CZ20394A3 (en) 1994-07-13
JP2960778B2 (ja) 1999-10-12
FI940435A (fi) 1994-01-28
TWI232217B (en) 2005-05-11
HU211333A9 (en) 1995-11-28
PH30983A (en) 1997-12-23
YU49259B (sh) 2004-12-31
BG61693B1 (bg) 1998-03-31
NO300842B1 (no) 1997-08-04
IL102616A (en) 1996-10-31
DE69233776D1 (de) 2009-12-31
US5618820A (en) 1997-04-08
AU659668B2 (en) 1995-05-25
CN1302612A (zh) 2001-07-11
GEP20002094B (en) 2000-05-10
PT526253E (pt) 2003-03-31
MD1434B2 (en) 2000-03-31
CA2114221C (fr) 2009-12-22
CN1074924C (zh) 2001-11-21
MD950114A (en) 1996-06-28
HK1038189A1 (en) 2002-03-08
TJ244R3 (en) 1999-11-24
EG20193A (en) 1997-10-30
HUT70030A (en) 1995-09-28

Similar Documents

Publication Publication Date Title
TNSN92070A1 (fr) Les analogues du necleoside de 13-oxathiolane
TNSN91029A1 (fr) Les analogues du nucleoside de 1,3-oxathiolane
RU94013464A (ru) Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции
HUP9801571A2 (hu) Zidovudin, 1592U89 és 3TC vagy FTC szinergetikus kombinációi
NO2005015I2 (no) Terapeutisk aktiv forbindelse preparat inneholdende forbindelsen samt den anvendelse
FI912328A0 (fi) Peptidfoerening och dess framstaellning.
HRP20050417B1 (hr) Antiviralni derivati nukleozida
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
ATE82294T1 (de) Therapeutische nukleoside.
BG100599A (en) Antiviral form and therapeutical method
ATE223428T1 (de) Nukleoside und nukleotide mit vergrösserten ringen
AR026255A1 (es) Combinaciones antivirales.
RU93058325A (ru) Применение производных 1,3-оксатиолана для получения лекарственных препаратов для лечения или профилактики вирусной инфекции гепатита в, применение производных 1,3 - оксатиолана для лечения инфекций гепатита в, способ лечения гепатита в
PE87398A1 (es) Combinaciones antivirales
MY137298A (en) Therapeutic nucleosides
EA200300430A1 (ru) Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин
NO20013599L (no) HIV-1-mutasjoner selektert for av <beta>-2',3'-didehydro- 2',3' -dideoksy-5-fluorcytidin
AR040805A1 (es) Composiciones que contienen tenofovir y emtricitabina y metodos para terapia antiviral
MY103900A (en) 6-substituted 2'', 3''-dideoxynucleosides and pharmaceutical compositions
AR013424A1 (es) Uso de uridina para la preparacion de una composicion farmaceutica util para inhibir la toxicidad de los analogos de pirimidina
CA2140238A1 (fr) Associations antivirales
AR007616A1 (es) Combinaciones antivirales
AR007615A1 (es) Combinaciones antivirales, formulaciones conteniendo las mismas, uso de los mismos en la manufactura de medicamentos y un articulo que los contiene.
TH13799EX (th) สารต้าน-เอชบีวี พิริมิดีนนิวคลีโอไซด์
MY113560A (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b